First, the business philosophy of Quzhou Yikangyuan Biotechnology Co., Ltd.:
With the vision of "industry first, shaping a healthy and beautiful home for human beings", the company has been committed to the research and development and production of food and feed nutritional fortifiers, introduced international advanced technology and equipment, and is in a leading position in the domestic biological fermentation field, especially in the production of high-end amino acids, vitamins and other products, and has accumulated rich experience and achieved fruitful results.
Second, the talent advantage of Quzhou Yikangyuan Biotechnology Co., Ltd.:
The main managers and professional technicians have rich experience in bio-fermentation industry, and have a team of professional talents with high academic level, excellent technology, rich experience and good management. The company has more than 10 core workshops and departments such as R&D center and fermentation workshop, which provides a strong organizational guarantee for the efficient operation of the whole company.
Three, Quzhou Yikangyuan Biotechnology Co., Ltd. Product quality:
The products have successively passed the ISO900 1 quality management system certification, ISO 1400 1 environmental management system certification, HACCP food safety management system certification, FAMI-QS European feed additive manufacturer operating standard system certification, kosher food certification and halal halal halal certification. The quality of products has reached the international first-class level and meets the standards for exporting to the European Union.
? Precautions:
1. The main profit model of international multinational pharmaceutical companies is still based on the research and development of innovative drugs. By investing a lot of money in research and development, they expect to get a "blockbuster" product and bring it to market quickly. Then, through high pricing and high gross profit during the patent period, huge profits can be made quickly.
2. Many countries regard biotechnology industry as a strategic industry with priority development in 2 1 century. At present, a few developed countries in Europe and America occupy an absolute proportion in the global biomedical market. There are more than 4,000 global biotechnology companies, 76% of which are concentrated in Europe and America, and the sales of European and American companies account for 93% of the global biotechnology companies' sales.